Clinical trial
A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen
NCT02875340 is registered in ClinicalTrials.gov with ValiSeek Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen
- Lead sponsor
- ValiSeek Limited
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- September 30, 2017
- Enrollment
- 8 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.